10-Q: Fate Therapeutics Narrows Losses, Advances Cell Therapies

Fate Therapeutics reported reduced net losses and operating expenses in its latest quarterly filing, driven by strategic restructuring and ongoing clinical development of its iPSC-derived cell immunotherapies.

Summary

• Net loss for the three months ended September 30, 2025, was $32.25 million, a significant reduction from $47.68 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $103.94 million, down from $134.11 million for the nine months ended September 30, 2024.
• Collaboration revenue decreased to $1.74 million for Q3 2025 from $3.07 million for Q3 2024, and to $5.28 million for the nine months ended September 30, 2025, from $11.77 million for the same period in 2024, primarily due to a non-recurring $5.0 million clinical development milestone in 2024.
• Research and development expenses decreased to $25.84 million for Q3 2025 from $34.65 million for Q3 2024, and to $82.40 million for the nine months ended September 30, 2025, from $101.39 million for the same period in 2024.
• General and administrative expenses decreased to $10.64 million for Q3 2025 from $20.80 million for Q3 2024, and to $35.86 million for the nine months ended September 30, 2025, from $58.91 million for the same period in 2024.
• Cash, cash equivalents, and investments totaled $225.7 million as of September 30, 2025.
• The accumulated deficit reached $1.5 billion as of September 30, 2025.
• A corporate restructuring in August 2025 included a workforce reduction of approximately 12%, incurring $1.1 million in severance costs.
• Received $3.8 million from the FT836 California Institute for Regenerative Medicine (CIRM) Award during the nine months ended September 30, 2025.
• Received $5.1 million from the FT819 CIRM Award as of September 30, 2025.
• The company exercised an early termination right for its Torrey Pines operating lease, effective October 31, 2025, with a $2.5 million payment made in 2024.

Sentiment

Score: 4

Explanation: While the company successfully reduced net losses and operating expenses through cost-cutting measures and secured some grant funding, the significant drop in collaboration revenue, continued substantial accumulated deficit, and ongoing need for external financing highlight persistent financial challenges. The novel nature of its technology also presents high development and regulatory risks, making commercial success uncertain. Legal proceedings add further uncertainty.

Positives

• Net losses significantly decreased for both the three-month ($32.25 million vs $47.68 million) and nine-month ($103.94 million vs $134.11 million) periods ended September 30, 2025, compared to the prior year.
• Operating expenses, including Research and Development ($25.84 million vs $34.65 million for Q3) and General and Administrative ($10.64 million vs $20.80 million for Q3), saw substantial reductions, reflecting successful cost-saving measures.
• Cash provided by investing activities was $83.5 million for the nine months ended September 30, 2025, a positive shift from cash used of $10.6 million in the prior year.
• Secured additional funding through CIRM awards, including $5.1 million received for the FT819 Phase 1 study and $3.8 million received for FT836 preclinical/IND-enabling activities.
• Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for FT819 for the treatment of active moderate to severe systemic lupus erythematosus, which may facilitate expedited development and review.
• Maintains an ongoing collaboration with Ono Pharmaceutical Co., Ltd. for iPSC-derived CAR T-cell and CAR NK cell product candidates, with committed funding through June 2026.

Negatives

• Collaboration revenue decreased significantly by $6.49 million (55%) for the nine months ended September 30, 2025, compared to the same period in 2024, primarily due to a non-recurring $5.0 million clinical development milestone recognized in 2024.
• The company continues to incur substantial net losses, with an accumulated deficit of $1.5 billion as of September 30, 2025, and anticipates continued significant operating losses for the foreseeable future.
• A corporate restructuring in August 2025 involved a workforce reduction of approximately 12%, indicating a need for operational streamlining and cost control.
• The company is highly dependent on substantial additional funding to complete preclinical and clinical development, obtain regulatory approval, and commercialize its product candidates.
• Stock price appreciation milestones under the Amended MSKCC License resulted in a $0.1 million expense for the three months ended September 30, 2025, indicating the stock price did not meet the appreciation threshold for income recognition.

Risks

• Product candidates represent novel therapeutic approaches and may cause undesirable side effects or have other properties that could delay or halt their preclinical or clinical development, prevent regulatory approval, limit commercial potential, or result in significant negative consequences.
• Failure to complete preclinical or clinical development or obtain regulatory approval for product candidates on a timely basis or at all would significantly harm the business.
• Development of product candidates will require substantial additional funding, which, if available, may cause dilution to stockholders, and without which preclinical or clinical development or regulatory approval cannot be completed.
• May elect to deprioritize or discontinue the clinical development of one or more product candidates for various reasons, including prioritization, data, or competitive landscape.
• Inability to use iPSC technology and gene-editing technology in product creation would significantly harm the business.
• Delays in initiating, conducting, or completing clinical trials, including difficulties recruiting appropriate clinical trial investigators, enrolling patients, or manufacturing adequate clinical supplies.
• Significant competition in an environment of rapid technological change from other biotechnology and pharmaceutical companies.
• Initial, interim, and preliminary data from preclinical studies or clinical trials may change as more data becomes available and are subject to audit and verification procedures.
• The manufacture and distribution of cell product candidates is complex and subject to a multitude of risks, potentially limiting supply and increasing costs.
• Inadequate funding for regulatory agencies (FDA, SEC, NIH) or changes in personnel could disrupt operations and hinder product development or commercialization.
• Limited experience manufacturing product candidates on a clinical scale and no experience manufacturing on a commercial scale.
• Dependence on third-party suppliers, including sole source suppliers, for certain equipment and components.
• Challenges recruiting and retaining key personnel due to labor market changes, availability of qualified candidates, and competition.
• Cost fluctuations and inflationary pressures may adversely impact operating performance, expenses, cash utilization, and results.
• Dependence on strategic partnerships and collaboration arrangements, which if unsuccessful or terminated, could result in delays and other obstacles.
• Limited operating history, significant accumulated losses, and anticipated continued losses for the foreseeable future.
• Inability to protect intellectual property or obtain and maintain patent protection could allow other companies to develop products based on discoveries, reducing demand.
• Failure to comply with intellectual property license agreements could lead to loss of rights to product candidates or key technologies.
• May not be successful in obtaining or maintaining necessary rights to product components and processes.
• No experience marketing any product candidates and no sales force or distribution capabilities.
• Commercial success depends on market acceptance by physicians, patients, third-party payers, and others in the medical community.
• Security breaches, loss of data, and other disruptions could compromise sensitive information and adversely impact operations.
• Principal stockholders and management own a significant percentage of stock and may be able to exercise significant control.
• Stock price is subject to fluctuation based on a variety of factors.
• Qualifying as a smaller reporting company and non-accelerated filer, and complying with only certain reduced reporting and disclosure requirements, could make stock less attractive to investors.
• Global economic and market conditions, public health emergencies, geopolitical tensions, or significant political, trade, economic, or regulatory developments could adversely impact various aspects of the business.
• Potential product liability exposure far in excess of limited insurance coverage.
• Employees or third-party service providers may engage in misconduct or other improper activities, including noncompliance with regulatory standards and insider trading.
• Risks of potential liability related to the privacy of personal information, including health information, and the increasing use of artificial intelligence-based software.
• Adverse developments affecting the financial services industry could adversely affect current and projected business operations and financial condition.
• Adverse impact from earthquakes, wildfires, power outages, or other natural disasters, including public health crises.
• Failure to maintain an effective system of disclosure controls and procedures and internal controls.
• Failure to comply with environmental, health, and safety laws and regulations.
• Changes in tax law may adversely affect the company or its investors.
• Subject to securities class action litigation and other types of stockholder litigation.
• Business operations may subject the company to disputes, claims, and lawsuits, which may be costly and time-consuming.

Future Outlook

The company anticipates continued significant operating losses for the foreseeable future, with expenses expected to remain high due to ongoing preclinical studies, clinical trials, GMP production, and intellectual property maintenance. Meaningful revenues from product sales, royalties, or sales milestones are not expected until successful development and regulatory approval, which is projected to take several years. The company plans to fund its operations through public or private equity or debt financings, collaboration arrangements, or other sources, acknowledging that additional capital will be required and may not be available on favorable terms. Future capital requirements are uncertain and depend on various factors, including clinical trial progress, manufacturing costs, regulatory approvals, and intellectual property expenses.

Management Comments

• We expect to continue to incur operating losses for at least the foreseeable future.
• We do not expect to generate any meaningful revenues from product sales, royalties, or sales milestones unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years.
• Our failure to raise capital or enter into such other arrangements when needed would have a negative effect on our financial condition and ability to develop our product candidates.
• We will require additional capital for the research, manufacture and development of our product candidates and to perform our obligations under our collaboration agreements, and we may need to seek additional funds sooner than expected.

Industry Context

Fate Therapeutics operates in the highly competitive and rapidly evolving biotechnology and pharmaceutical industries, with a specific focus on immune-oncology and cell therapies. The company is pioneering iPSC-derived cellular immunotherapies, a novel and unproven technology, with no iPSC-derived therapeutic product candidates currently approved globally. It is expanding its research and development efforts into autoimmune diseases, an area where it has limited prior experience and where no FDA-approved cell therapies exist, implying a higher risk profile and lower tolerance for adverse events compared to established oncology indications. The company faces intense competition from larger pharmaceutical companies, multinational biopharmaceutical firms, specialized biotechnology companies, and academic institutions, many of which possess greater financial and other resources. The regulatory landscape for cell and gene therapies is dynamic, with evolving requirements and potential changes in regulatory pathways, as evidenced by the FDA's elevation of the Office of Therapeutic Products and its cautions regarding T-cell malignancies in CAR T-cell therapies.

Comparison to Industry Standards

• No iPSC-derived therapeutic product candidates have been approved in the United States or worldwide to date, indicating Fate Therapeutics is operating at the forefront of a novel, unproven technology, making direct comparisons to approved products difficult.
• Currently approved CAR T-cell therapies and those under development have shown frequent rates of adverse events, including infection, cytokine release syndrome (CRS), and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), setting a benchmark for safety concerns that Fate's CAR T-cell and CAR NK cell candidates also face.
• The tolerance for adverse events in autoimmune disease patient populations, which Fate Therapeutics is targeting with FT819, is expected to be lower than in oncology, posing a greater challenge for its autoimmune programs compared to the established oncology cell therapy market.
• Several companies with experience in oncology CAR T-cell therapies have recently commenced development of cell therapies for autoimmune diseases, indicating emerging competition in this novel therapeutic area, though specific comparable companies or results are not detailed in the filing.

Management Changes

Corporate Governance

Legal Proceedings

• **Securities Class Action Lawsuit (Hadian v. Fate Therapeutics, Inc. et al.)**: Filed January 20, 2023, alleging false and/or misleading statements/omissions related to the Janssen Agreement and its termination. The court granted motions to dismiss on September 19, 2024, and September 22, 2025, each with leave for the plaintiff to file an amended complaint. A third amended complaint was filed on October 17, 2025, and the company intends to file a motion to dismiss by November 17, 2025.
• **Derivative Actions (Guarino v. Wolchko, et al. and Horrobin v. Wolchko, et al.)**: Filed June 2, 2023, and June 12, 2024, respectively, and consolidated as In re Fate Therapeutics, Inc. Derivative Litigation. These actions assert derivative claims arising from substantially the same alleged facts as the Securities Action, including breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, violation of federal securities laws, and insider trading. The Derivative Action was stayed pending the Securities Action decision, the stay expired on September 22, 2025, and was subsequently extended on October 24, 2025, pending the court's decision on the anticipated motion to dismiss the third amended complaint in the Securities Action.

Related Party Transactions

• Redmile Group, LLC, an entity affiliated with directors and officers, purchased convertible preferred stock and common stock in a private placement in November 2016.
• Redmile Group, LLC purchased pre-funded warrants in a private placement concurrent with the March 2024 public offering.
• Redmile Group, LLC increased its beneficial ownership limitation from 9.99% to 14.99%, effective August 31, 2025.
• Executive officers, directors, and entities affiliated with five percent stockholders beneficially own approximately 39.8% of the outstanding voting stock (potentially 43.7% if Class A Preferred is fully converted).

Stakeholder Impact

• **Shareholders**: Face potential dilution from future equity capital raises, continued stock price volatility, and the impact of ongoing legal proceedings. The significant ownership by principal stockholders and management could influence corporate decisions.
• **Employees**: Experienced a workforce reduction of approximately 12% in August 2025, which may affect morale and retention. The change in CEO role represents a leadership transition.
• **Customers/Patients**: Benefit from the continued development of novel iPSC-derived cellular immunotherapies for cancer and autoimmune diseases. The RMAT designation for FT819 could potentially expedite its availability for patients with systemic lupus erythematosus.
• **Creditors**: The accumulated deficit of $1.5 billion and anticipated future losses indicate ongoing financial risk, although the company has a cash and investment balance of $225.7 million.
• **Suppliers/Partners**: The company's dependence on third-party suppliers for materials and equipment, and collaboration partners (Ono, MSKCC, CIRM) for research, development, and funding, means their operational stability and performance are critical to Fate Therapeutics' success.

Next Steps

• Conduct ongoing and planned preclinical studies and clinical trials of product candidates.
• Conduct Good Manufacturing Practice (GMP) production, process and scale-up development, and technology transfer activities for product candidates.
• Procure laboratory equipment, materials, and supplies for manufacturing and research activities.
• Conduct preclinical and clinical research to investigate the therapeutic activity of product candidates.
• Continue research, development, and manufacturing activities, including under the sponsored research and collaboration agreement with Ono.
• Maintain, prosecute, protect, expand, and enforce the intellectual property portfolio.
• Engage with regulatory authorities for the development of, and seek regulatory approvals for, product candidates.
• Continue operating as a public company and support operations.
• File a motion to dismiss the third amended complaint in the Securities Action by November 17, 2025.
• Plaintiff to file any opposition brief for the third amended complaint by December 18, 2025.
• Company to file its reply in support of its motion to dismiss the third amended complaint by January 15, 2026.

Key Dates

Recommendation

While Fate Therapeutics has demonstrated improved financial efficiency by significantly reducing net losses and operating expenses, and has secured grant funding for key programs (FT819 RMAT designation), the company continues to operate at a substantial loss with a large accumulated deficit. Collaboration revenue saw a notable decline due to non-recurring milestones from the prior year. The company's reliance on novel, unproven iPSC technology for its product pipeline introduces high development and regulatory risks, and it will require significant additional capital to reach commercialization. Ongoing legal proceedings add further uncertainty. Given the early stage of its pipeline, the high-risk nature of its technology, and the need for substantial future funding, a 'hold' recommendation is appropriate. Investors should monitor clinical trial progress, regulatory milestones, and future financing activities closely.

Keywords

iPSC, cellular immunotherapy, CAR T-cell, CAR NK cell, oncology, autoimmune disease, FT819, FT836, biopharmaceutical, clinical-stage, gene editing, SEC filing, 10-Q, Fate Therapeutics, regenerative medicine